This company has been acquired
OPNT Stock Overview
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Opiant Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.65 |
| 52 Week High | US$28.15 |
| 52 Week Low | US$7.34 |
| Beta | 0.83 |
| 1 Month Change | 3.10% |
| 3 Month Change | 2.38% |
| 1 Year Change | -22.31% |
| 3 Year Change | 70.80% |
| 5 Year Change | 1.77% |
| Change since IPO | -82.79% |
Recent News & Updates
Recent updates
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates
Aug 13
Opiant awarded additional $2.1M from BARDA for its nasal opioid overdose treatment
Aug 08Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate
Aug 05Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts
Mar 21Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News
Nov 19These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well
Nov 17Opiant Pharmaceuticals: Assessing Recent Insider Buying
Sep 19Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts
Aug 07Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)
Jun 09The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts
Mar 06News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts
Mar 05Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.
Jan 27Shareholder Returns
| OPNT | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -1.3% | 1.8% | 0.5% |
| 1Y | -22.3% | -10.1% | 11.1% |
Return vs Industry: OPNT underperformed the US Pharmaceuticals industry which returned -3.7% over the past year.
Return vs Market: OPNT underperformed the US Market which returned 14.1% over the past year.
Price Volatility
| OPNT volatility | |
|---|---|
| OPNT Average Weekly Movement | 1.5% |
| Pharmaceuticals Industry Average Movement | 11.4% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: OPNT has not had significant price volatility in the past 3 months.
Volatility Over Time: OPNT's weekly volatility has decreased from 19% to 1% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 38 | Roger Crystal | www.opiant.com |
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders.
Opiant Pharmaceuticals, Inc. Fundamentals Summary
| OPNT fundamental statistics | |
|---|---|
| Market cap | US$108.80m |
| Earnings (TTM) | -US$33.09m |
| Revenue (TTM) | US$22.34m |
Is OPNT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OPNT income statement (TTM) | |
|---|---|
| Revenue | US$22.34m |
| Cost of Revenue | US$29.45m |
| Gross Profit | -US$7.11m |
| Other Expenses | US$25.97m |
| Earnings | -US$33.09m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.28 |
| Gross Margin | -31.85% |
| Net Profit Margin | -148.12% |
| Debt/Equity Ratio | 67.1% |
How did OPNT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/03/03 12:57 |
| End of Day Share Price | 2023/03/01 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Opiant Pharmaceuticals, Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Louise Chen | Cantor Fitzgerald & Co. |
| Brandon Folkes | Cantor Fitzgerald & Co. |
| Carl Byrnes | Northland Capital Markets |